September 27, 2016 10:50 PM ET

Biotechnology

Company Overview of Aileron Therapeutics, Inc.

Key Executives for Aileron Therapeutics, Inc.

NameBoard RelationshipsTitleAge
Joseph A. Yanchik III, Esq.24 RelationshipsFounder, Chief Executive Officer, President and Director52
Huw M. Nash Ph.D.No RelationshipsCo-Founder--
Evan Lippman No RelationshipsChief Financial Officer, Senior Vice President and Business Officer--
Manuel C. Aivado M.D., Ph.D.No RelationshipsChief Medical Officer and Senior Vice President--
D. Allen Annis Ph.D.No RelationshipsVice President of Biophysical and Analytical Technologies--

Aileron Therapeutics, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Scott Bancroft Kapnick 21 RelationshipsHPS Investment Partners, LLC57
Joseph A. Yanchik III, Esq. 24 RelationshipsAileron Therapeutics, Inc.52
David G. Nathan M.D. 57 RelationshipsAileron Therapeutics, Inc.--
Michael B. Kastan M.D., Ph.D. 14 RelationshipsAileron Therapeutics, Inc.--
Loren D. Walensky M.D., Ph.D. 14 RelationshipsAileron Therapeutics, Inc.--
View All Board Members

Aileron Therapeutics, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
There is no committee data available.
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary
383.7K
Bonus
264.0K
Total Short Term Compensation
479.1K
Total Value of Options
33.3M
Compensation as of Fiscal Year
Aileron Therapeutics, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Navidea Biopharmaceuticals, Inc Announces Executive Changes
September 26, 2016 9:00 PM ET
Prothena Corporation plc Announces Dale B. Schenk, President and Chief Executive Officer, Is Taking A Medical Leave of Absence
September 26, 2016 8:12 PM ET
Syros Pharmaceuticals Appoints Gerald E. Quirk as Chief Legal Officer
September 26, 2016 12:05 PM ET
Intrexon Corporation Appoints Thomas P. Bostick as Head of Environment Sector
September 26, 2016 12:00 PM ET
Swedish Orphan Biovitrum AB Announces Appointment of Milan Zdravkovic as Senior Vice President, Head of Research & Development
September 26, 2016 10:04 AM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Aileron Therapeutics, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.